Company-sponsored, randomized, placebo-controlled trial to test the safety and efficacy of two doses of masitinib (3 or 6 mg per kg per day), as measured by changes in the MS functional composite score (primary outcome)

A clinical response to treatment was reported in some participants, but the response was not statistically significant; masitinib was also associated with a higher incidence of severe adverse events than was placebo